Transformations in the Life Sciences is the focus of the second season of the MedCity Pivot Podcast. My personal journey as a caregiver of a cancer patient made me choose Dr. Sumanta Pal, co-director of the City of Hope's Liver Cancer program as a guest after he co-authored an interesting study on immunotherapy that was published in the Lancet.
Bristol Myers Squibb and Nektar Therapeutics are ending a cancer drug research alliance after data showed the combination of their respective drugs failed clinical trials in kidney and bladder cancers. The disappointing results come one month after the drug combo failed a pivotal melanoma clinical trial.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
FDA approval of a therapy that pairs drugs from Eisai and Merck allows the combination to become a first-line treatment for renal cell carcinoma. It’s the latest approval for the partners, which have been working together since 2018.
The agency told the company it still had lingering reservations about the results of a Phase III trial that had been designed to allay agency concerns. Shares of the company fell 38 percent on the news.
The ability to more accurately define the different types of cancer, it could lead to lowering costs for treatment and reducing complications.
Regina Holliday is a well-known patient advocate, activist and artist. A widow and mother, she fights for patient empowerment through her paintings, writing and even her Twitter. (Follow her. You won’t regret it.) She is also the mind (and paintbrush) behind the Walking Gallery, a movement devoted to patients and healthcare leaders wearing their stories […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.